Variant report
Variant | esv1817587 |
---|---|
Chromosome Location | chr5:5103652-5109824 |
allele | n/a |
Outlinks | Ensembl   UCSC |
- TF binding region (count:0)
- CpG islands (count:0)
- Chromatin interactive region (count:0)
- LncRNA region (count:0)
- Mature miRNA region (count: 0)
- miRNA target sites (count:0)
No data |
No data |
No data |
No data |
No data |
No data |
No data |
No. | Variant name | Chromosome position | Chromatin state | Related regulatory elements | Target genes | Extended variants | Associated traits |
---|---|---|---|---|---|---|---|
1 | rs28706238 | chr5:5103652-5103653 | Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
2 | rs542684507 | chr5:5103660-5103661 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
3 | rs73738330 | chr5:5103666-5103667 | Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
4 | rs576182441 | chr5:5103667-5103668 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
5 | rs545193383 | chr5:5103684-5103685 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
6 | rs150744557 | chr5:5103704-5103705 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
7 | rs369472483 | chr5:5103713-5103714 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
8 | rs568998630 | chr5:5103729-5103730 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
9 | rs540248727 | chr5:5103781-5103782 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
10 | rs560241147 | chr5:5103830-5103831 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
11 | rs559862995 | chr5:5103865-5103866 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
12 | rs528997329 | chr5:5103969-5103970 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
13 | rs190052458 | chr5:5103983-5103984 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
14 | rs569078409 | chr5:5104028-5104029 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
15 | rs78145025 | chr5:5104071-5104072 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
16 | rs74582601 | chr5:5104072-5104073 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
17 | rs372517455 | chr5:5104084-5104085 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
18 | rs74288235 | chr5:5104108-5104109 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
19 | rs28392909 | chr5:5104149-5104150 | Weak transcription | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
20 | rs547793279 | chr5:5104155-5104156 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
21 | rs182640478 | chr5:5104187-5104188 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
22 | rs540241364 | chr5:5104190-5104191 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
23 | rs149715387 | chr5:5104191-5104192 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
24 | rs860953 | chr5:5104198-5104199 | Weak transcription | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
25 | rs553968109 | chr5:5104200-5104201 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
26 | rs139116135 | chr5:5104219-5104220 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
27 | rs576118597 | chr5:5104248-5104249 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
28 | rs538634582 | chr5:5104270-5104271 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
29 | rs16874707 | chr5:5104273-5104274 | Weak transcription | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | mRNA abundance |
30 | rs185569925 | chr5:5104320-5104321 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
31 | rs575248747 | chr5:5104356-5104357 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
32 | rs572718938 | chr5:5104406-5104407 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
33 | rs200815235 | chr5:5104445-5104446 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
34 | rs191405973 | chr5:5104447-5104448 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
35 | rs560100072 | chr5:5104460-5104461 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
36 | rs573635815 | chr5:5104495-5104496 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
37 | rs542644948 | chr5:5104501-5104502 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
38 | rs183684180 | chr5:5104510-5104511 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
39 | rs562616028 | chr5:5104576-5104577 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
40 | rs531420990 | chr5:5104599-5104600 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
41 | rs551632392 | chr5:5104605-5104606 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
42 | rs73032456 | chr5:5104668-5104669 | Enhancers Weak transcription | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
43 | rs527599320 | chr5:5104735-5104736 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
44 | rs547328378 | chr5:5104745-5104746 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
45 | rs567548536 | chr5:5104749-5104750 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
46 | rs536287080 | chr5:5104756-5104757 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
47 | rs369347910 | chr5:5104760-5104761 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
48 | rs554880204 | chr5:5104767-5104768 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
49 | rs542838617 | chr5:5104773-5104774 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
50 | rs538716976 | chr5:5104776-5104777 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
Disease | PMID | Source |
---|---|---|
Glioblastoma multiforme | 22286061 | CNVD |
Lung cancer | 21911935 | CNVD |
Cri-du chat syndrome | 21549014 | CNVD |
Cervical squamous cell carcinoma | 21590768 | CNVD |
Melanoma | 18172304 | CNVD |
Non-syndromic sensorineural hearing loss | 20606397 | CNVD |
Sudden cardiac death | 19188705 | CNVD |
renal disease | 17924346 | CNVD |
abnormal development | 18461090 | CNVD |
Lung cancer | 19547694 | CNVD |
Cri-du chat syndrome | 22283845 | CNVD |
Disorders of sex development | 21048976 | CNVD |
Non-small cell lung cancer | 20864512 | CNVD |
Cancer | 21183584 | CNVD |
Honadal dysgenesis | 21048976 | CNVD |
Cancer | 16751803 | CNVD |
Breast cancer | 17133270 | CNVD |
Hepatocellular carcinoma | 22174799 | CNVD |
Chronic lymphocytic leukemia | 21546498 | CNVD |
Salivary gland tumor | 18059337 | CNVD |
Endometrioid adenocarcinoma | 16974079 | CNVD |
Kartagener syndrome | 16639409 | CNVD |
Medulloblastoma | 21979893 | CNVD |
Myofibroblastic sarcoma | 19369631 | CNVD |
Esophageal squamous carcinoma | 21637470 | CNVD |
Glioblastoma multiforme | 21080181 | CNVD |
Medulloblastoma | 16783165 | CNVD |
Thyroid cancer | 19087340 | CNVD |
Liposarcoma | 21253554 | CNVD |
Pancreatic endocrine tumor | 17639061 | CNVD |
Cervical Cancer | 21857958 | CNVD |
Cervical cancer | 21062161 | CNVD |
Ewing''s sarcoma | 21437220 | CNVD |
Glioblastoma multiforme | 19960244 | CNVD |
Oral cancer | 21386901 | CNVD |
Astrocytoma | 17387387 | CNVD |
Breast cancer | 21264507 | CNVD |
Acute lymphoblastic leukemia | 20067559 | CNVD |
Esophageal squamous carcinoma | 18350619 | CNVD |
Ewing''s sarcoma | 17952124 | CNVD |
Malignant mesothelioma | 18160781 | CNVD |
Pleural malignant mesothelioma | 18160781 | CNVD |
Cervical cancer | 18559093 | CNVD |
Basal cell lymphoma | 16317097 | CNVD |
Diffuse large b-cell lymphoma | 16317097 | CNVD |
Metanephric adenoma | 20802469 | CNVD |
Acute lymphoblastic leukemia | 17690704 | CNVD |
Gastrointestinal stromal cancer | 16982739 | CNVD |
Phyllodes tumor | 17334353 | CNVD |
Malaria | 21533027 | CNVD |
Renal cell carcinoma | 19461508 | CNVD |
Colorectal cancer | 21645411 | CNVD |
Gastric cancer | 22152101 | CNVD |
Oesophago-gastric ulcer | 22152101 | CNVD |
Ovarian cancer | 21781307 | CNVD |
T-cell prolymphocytic leukemia | 17713554 | CNVD |
Breast cancer | 20668451 | CNVD |
Cancer | 20668451 | CNVD |
Lung cancer | 20668451 | CNVD |
Ovarian cancer | 20668451 | CNVD |
Pancreas cancer | 20668451 | CNVD |
Prostate cancer | 20668451 | CNVD |
Cancer | 20164919 | CNVD |
T-cell prolymphocytic leukemia | 19278963 | CNVD |
Acute lymphoblastic leukemia | 20435627 | CNVD |
Thoracic aortic aneurysm | 21092924 | CNVD |
low-grade B-cell lymphoma tumor | 18367492 | CNVD |
Multiple myeloma | 17550852 | CNVD |
Pleomorphic liposarcoma | 18784837 | CNVD |
Developmental delay | 21147756 | CNVD |
prenatal diagnosis | 22389664 | CNVD |
Bladder cancer | 21909424 | CNVD |
DNA damage stimulus | 22844521 | CNVD |
DNA repair | 22844521 | CNVD |
Breast cancer | 21785460 | CNVD |
Spinal muscular atrophy | 22422766 | CNVD |
Spinal muscular atrophy | 22558076 | CNVD |
Spinal muscular atrophy | 21320981 | CNVD |
Spinal muscular atrophy | 21762474 | CNVD |
Breast cancer | 21858162 | CNVD |
Prostate cancer | 18632612 | CNVD |
Esophageal adenocarcinoma | 19417022 | CNVD |
Melanoma | 22183965 | CNVD |
Breast cancer | 21364760 | CNVD |
small cell lung cancer | 20016488 | CNVD |
Lung cancer | 18438408 | CNVD |
lymphocytic leukemia | 21291569 | CNVD |
Autism | 22495311 | CNVD |
Gastrointestinal stromal cancer | 20818650 | CNVD |
Schizophrenia | 23813976 | CNVD |
Hodgkin''s lymphoma | 17606441 | CNVD |
Breast cancer | 16608533 | CNVD |
Anaplastic large cell lymphoma | 18179710 | CNVD |
Non-syndromic sensorineural hearing loss | 17122850 | CNVD |
Breast cancer | 22522925 | CNVD |
Non-syndromic sensorineural hearing loss | 18451855 | CNVD |
No. | Chromosome Location | Chromatin state | Cell line | Tissue |
---|---|---|---|---|
1 | chr5:5103200-5103800 | Enhancers | HSMM | muscle |
2 | chr5:5103800-5105200 | Weak transcription | HSMM | muscle |
3 | chr5:5104400-5105400 | Enhancers | NHEK | skin |
4 | chr5:5104400-5106400 | Enhancers | HMEC | breast |
5 | chr5:5104600-5104800 | Enhancers | ES-WA7 Cell Line | embryonic stem cell |
6 | chr5:5104600-5104800 | Enhancers | Fetal Kidney | kidney |
7 | chr5:5104600-5105400 | Enhancers | Foreskin Keratinocyte Primary Cells skin02 | Skin |
8 | chr5:5104800-5105200 | Weak transcription | ES-WA7 Cell Line | embryonic stem cell |
9 | chr5:5105200-5106400 | Enhancers | HSMM | muscle |
10 | chr5:5105400-5105800 | Weak transcription | Foreskin Keratinocyte Primary Cells skin02 | Skin |
11 | chr5:5105400-5106000 | Weak transcription | NHEK | skin |
12 | chr5:5105800-5106400 | Enhancers | Foreskin Keratinocyte Primary Cells skin02 | Skin |
13 | chr5:5106000-5106200 | Enhancers | NHEK | skin |
14 | chr5:5108000-5108200 | Enhancers | ES-I3 Cell Line | embryonic stem cell |
15 | chr5:5108000-5108600 | Enhancers | HUES6 Cell Line | embryonic stem cell |
16 | chr5:5108200-5115400 | Weak transcription | ES-I3 Cell Line | embryonic stem cell |
17 | chr5:5108400-5108800 | Enhancers | HUES48 Cell Line | embryonic stem cell |
18 | chr5:5108400-5109000 | Enhancers | iPS-15b Cell Line | embryonic stem cell |